Trulicity 0.75mg Prefilled Insulin Pen

✔️ Uses of Trulicity 0.75mg Prefilled Insulin Pen

• Used to manage type II diabetes mellitus along with diet and exercise

✔️ Side Effects of Trulicity 0.75mg Prefilled Insulin Pen

The common side effects of Trulicity 0.75mg Prefilled Insulin Pen (Dulaglutide) may include:

• Low blood sugar: Also known as hypoglycemia, it can manifest as symptoms such as shakiness, dizziness, sweating, and confusion.
• Nausea and vomiting: A feeling of discomfort in the stomach with a tendency to vomit.
• Diarrhea: Frequent and loose bowel movements.
• Abdominal (stomach) pain: Discomfort or pain in the abdominal area.
• Decreased appetite: Feeling less hungry than usual.
• Indigestion: Difficulty in digesting food, often accompanied by discomfort or burning sensations.
• Constipation: Difficulty in passing stools, often associated with infrequent bowel movements.
• Stomach bloating: A feeling of fullness or tightness in the abdomen due to excess gas.

If you experience any of the following serious side effects, stop receiving Trulicity 0.75mg Prefilled Insulin Pen and contact your doctor immediately:

Anaphylactic reactions, angioedema: Symptoms include rashes, itching, rapid swelling of the tissues of the neck, face, mouth, or throat, hives, and difficulties breathing. These are severe allergic reactions that require immediate medical attention.

✔️ How does Trulicity 0.75mg Prefilled Insulin Pen work?

Trulicity 0.75mg Prefilled Insulin Pen activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in the pancreatic beta cells. GLP-1, or glucagon-like peptide-1, is a natural hormone that plays a crucial role in blood sugar regulation. When GLP-1 binds to its receptor, it triggers a series of events that contribute to the management of blood glucose levels:

• Increased Insulin Production: GLP-1 stimulates the pancreas to produce more insulin. Insulin is essential for the uptake of glucose by cells, promoting its conversion into energy.
• Blood Sugar Control: By enhancing insulin production, GLP-1 helps maintain blood glucose levels within the normal range. This is particularly important after meals when blood sugar tends to rise.
• Optimal Insulin Release: GLP-1 aids the pancreas in releasing the right amount of insulin in response to elevated blood sugar levels. This contributes to a more precise and balanced insulin response.
• Enhanced Sugar Utilization: Insulin, facilitated by GLP-1, assists in transporting sugar from the bloodstream into various body tissues. This process allows cells to utilize sugar for energy.

The overall effect of Trulicity 0.75mg Prefilled Insulin Pen's activation of the GLP-1 receptor is improved blood sugar control, especially in individuals with type 2 diabetes where there may be insufficient insulin production or decreased sensitivity to insulin.

✔️ Quick Suggestions:

• You can inject Trulicity 0.75mg Prefilled Insulin Pen into the same body area each week, but try not to use the same spot.
• Store the pen in the refrigerator. When refrigeration is not possible, you can also keep your pen at room temperature (less than 30°C) for up to 2 weeks. Do not freeze it.
• Do not use Trulicity 0.75mg Prefilled Insulin Pen if particles appear or if the solution is cloudy and/or discolored.
• Trulicity 0.75mg Prefilled Insulin Pen may cause nausea, vomiting, diarrhea, or stomach pain, which may get better with time. Eat smaller meals, limit fatty food intake, and inform your doctor if it does not go away.

✔️ Indications

Trulicity (Dulaglutide) in the strength of 0.75 mg/0.5 ml is a glucagon-like peptide-1 (GLP-1) receptor agonist with the following indications:

• As an adjunct to diet and exercise: Trulicity is used to improve glycemic control in adults with type 2 diabetes mellitus. It works by stimulating the GLP-1 receptors, which leads to increased insulin release, reduced glucagon secretion, and delayed gastric emptying.
• To reduce the risk of major adverse cardiovascular events: Trulicity is also prescribed for adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. Its use in this context aims to lower the risk of major adverse cardiovascular events.

✔️ Pharmacology

Trulicity 0.75mg Prefilled Insulin Pen contains Dulaglutide, which is a human GLP-1 receptor agonist. It shares a 90% amino acid sequence homology with endogenous human GLP-1 (7-37). The mechanism of action of Trulicity 0.75mg Prefilled Insulin Pen involves the activation of the GLP-1 receptor, a membrane-bound cell-surface receptor that is coupled to adenylyl cyclase in pancreatic beta cells.

Key actions of Trulicity 0.75mg Prefilled Insulin Pen include:

• GLP-1 Receptor Activation: Trulicity activates the GLP-1 receptor, leading to a cascade of intracellular events.
• Increased cAMP Levels: This activation results in an increase in intracellular cyclic AMP (cAMP) within beta cells.
• Glucose-Dependent Insulin Release: The rise in cAMP levels is glucose-dependent, leading to the release of insulin from beta cells when blood glucose levels are elevated.
• Decreased Glucagon Secretion: Trulicity also decreases the secretion of glucagon, a hormone that raises blood sugar levels.
• Slowed Gastric Emptying: Additionally, Trulicity slows down the emptying of the stomach.

These combined effects contribute to better glycemic control by promoting insulin release, inhibiting glucagon secretion, and slowing down the absorption of glucose from the digestive system.

✔️ Dosage:

The recommended initial dose of Trulicity 0.75mg Prefilled Insulin Pen is 0.75 mg administered once weekly. This dose can be increased to 1.5 mg once weekly for additional glycemic control. The maximum recommended dose is 1.5 mg once weekly.

✔️ Administration:

Here are the administration instructions for Trulicity 0.75mg Prefilled Insulin Pen:

• Administer once weekly at any time of the day.
• It can be taken with or without food.
• The injection should be given subcutaneously in the abdomen, thigh, or upper arm.

✔️ If a dose is missed:

• If there are at least 3 days (72 hours) until the next scheduled dose, administer the missed dose as soon as possible.
• If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day.
• In both cases, patients can then resume their regular once-weekly dosing schedule.
• The day of weekly administration can be changed if necessary, as long as the last dose was administered 3 or more days before.

✔️ Interaction

Trulicity 0.75mg Prefilled Insulin Pen has the potential to slow gastric emptying, which may affect the absorption of concomitantly administered oral medications. Caution is advised when oral medications are given with Trulicity 0.75mg Prefilled Insulin Pen, especially for drugs with a narrow therapeutic index. Monitoring drug levels of medications with a narrow therapeutic index is recommended when co-administered with Trulicity 0.75mg Prefilled Insulin Pen. However, in clinical pharmacology studies, Trulicity 0.75mg Prefilled Insulin Pen did not significantly impact the absorption of the tested, orally administered medications to a clinically relevant degree.

✔️ Contraindications for Trulicity 0.75mg Prefilled Insulin Peninclude:

• Medullary Thyroid Carcinoma: Contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
• Multiple Endocrine Neoplasia Syndrome Type 2: Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2.
• Hypersensitivity: Contraindicated in patients with a prior serious hypersensitivity reaction to Trulicity 0.75mg Prefilled Insulin Pen or any of its components.

Patients with these conditions should avoid the use of Trulicity 0.75mg Prefilled Insulin Pen due to potential risks associated with these contraindications.

✔️ Pregnancy & Lactation

• Trulicity 0.75mg Prefilled Insulin Pen should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
• Data on the presence of Trulicity 0.75mg Prefilled Insulin Pen in human milk, its effects on the breastfed infant, or its effects on milk production are not available.
• The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Trulicity 0.75mg Prefilled Insulin Pen, weighing any potential adverse effects on the breastfed infant.

✔️ Precautions & Warnings

Pancreatitis:

• Reported in clinical trials.
• Discontinue promptly if pancreatitis is suspected.
• Do not restart if pancreatitis is confirmed.
• Consider other antidiabetic therapies in patients with a history of pancreatitis.

Hypoglycemia:

• When used with an insulin secretagogue (e.g., a sulfonylurea) or insulin, consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia.

Hypersensitivity Reactions:

• Serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) have occurred.
• Discontinue Trulicity 0.75mg Prefilled Insulin Pen and promptly seek medical advice.

Acute Kidney Injury:

• Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.

Severe Gastrointestinal Disease:

• Use may be associated with gastrointestinal adverse reactions, sometimes severe.
• It has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients.

Diabetic Retinopathy Complications:

• Reported in a cardiovascular outcomes trial.
• Monitor patients with a history of diabetic retinopathy.

✔️ Storage Conditions

• Store Trulicity 0.75mg Prefilled Insulin Pen in the refrigerator at 2°C to 8°C.
• Do not use Trulicity 0.75mg Prefilled Insulin Pen beyond the expiration date.
• If needed, each single-dose pen can be kept at room temperature, not exceeding 30°C, for a total of 14 days.
• Do not freeze Trulicity 0.75mg Prefilled Insulin Pen.

✔️

1: 

Q2: 

Q3: